1 |
Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991;13:274-9
DOI
ScienceOn
|
2 |
Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankroff J, et al. Adrenoleukodystrophy : phenotypic variability and implications for therapy. J Inher Metab Dis 1992;15:645-64
DOI
ScienceOn
|
3 |
Rizzo WB, Phillips MW, Dammann AL, Leshner RT, Jennings SS, Avigan J, et al. Adrenoleukodystrophy : dietary oleic acid lowers hexacosanoate levels. Ann Neurol 1987;21: 232-9
DOI
ScienceOn
|
4 |
Janet B, Jannifer C. ALD-AMN diet cookbook. Sycamore : United Leukodystrophy Foundation, 1990:1-20
|
5 |
Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990;322:1860-6
DOI
ScienceOn
|
6 |
Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M, et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000;356:713-8
DOI
ScienceOn
|
7 |
Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999;269:71-4
DOI
ScienceOn
|
8 |
Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleu-kodystrophy brain after treatment with Lorenzo's oil. Ann Neurol 1994;36:741-6.
DOI
ScienceOn
|
9 |
Rizzo WB, Watkins PA, Phillips MW, Cranin D, Campbell B, Avigan J. Adrenoleukodystrophy : oleic acid lowers fibroblast saturated C22-26 fatty acids. Neurology 1986;36:357- 61
DOI
|
10 |
Brown FR 3rd, van Duyn MA, Moser AB, Schulman JD, Rizzo WB, Snyder RD, et al. Adrenoleukodystrophy : effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J 1982;151: 164-72
|
11 |
Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adrenoleukodystrophy : cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992;51:630-43
DOI
PUBMED
|
12 |
Moser HW, Smith KD, Watkins PA, Powers J, Moser AB. X-linked adrenoleukodystrophy. In : Scriver CR, Beaudet AL, editors. The metabolic & molecular bases of inherited disease. 8th ed. New York : McGraw-Hill company, 2001: 3257-301
|
13 |
Odone A, Odone M. Lorenzo's oil : a new treatment for adrenoleukodystrophy. J Pediatr Neurosci 1989;5:55-61
DOI
ScienceOn
|
14 |
Singh I, Pahan K, Kahn M. Lovastatin and sodium phenylacetate normalize the levels of very-long-chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS Lett 1998;426:342-6
DOI
ScienceOn
|
15 |
Rizzo WB, Leshner RT, Odone A, Damman AL, Craft DA, Jensone ME, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989;39:1415-22
DOI
|
16 |
Bourre JM, Daudu O, Baumann N. Nervonic acid biosynthesis by erucyl-coA elongation in normal and quaking mouse brain microsomes. Elongation of other unsaturated fatty acyl-coAs(mono and polyunsaturated). Biochim Biophys Acta 1976;424:1-7
DOI
ScienceOn
|
17 |
Korenke GC, Hunneman DH, Kohler J, StOckler S, Landmark K, Hanefeld F. Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/ adrenomyeloneuropathy : effect on clinical, biochemical, and neurophysiological parameters. Eur J Pediatr 1995; 154:64-70
DOI
ScienceOn
|
18 |
Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 1999;12:167-76
DOI
ScienceOn
|
19 |
Moser HW, Borel J. Dietary management of X-linked adrenoleukodystrophy. Annu Rev Nutr 1995;15:379-97
DOI
ScienceOn
|
20 |
Weinhofer I, Forss-Petter S, Zigman M, Berger J. Cholesterol regulates ABCD2 expression : implications for the therapy of X-linked adrenoleukodystrophy. Hum Mol Genet 2002;11:2701-8
DOI
ScienceOn
|
21 |
Koc ON, Day J, Nieder M, Gerson SL, Luzarus HM, Krivit W. Allogenic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy(MLD) and Hurler syndrome( MPS-IH). Bone Marrow Transplant 2002;30:215-22.
DOI
ScienceOn
|
22 |
Asano J, Sujuki Y, Yajima S, Inoue K, Shimozawa N, Kondo N, et al. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev 1994;16:454-8
DOI
ScienceOn
|
23 |
Moser HW, Fatemi A, Zackowski K, Smith S, Golay X, Muenz L, et al. Evaluation of therapy of X-linked adrenoleukodystrophy. Neurochem Res 2004;29:1003-16
DOI
ScienceOn
|
24 |
Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaque I, et al. A two-year trial of oleic acid and erucic acids('Lorenzo's oil') as treatment for adrenomyeloneuropathy. N Engl J Med 1993;329:745-52.
DOI
ScienceOn
|
25 |
Moser HW. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 1995;54:740-5
DOI
PUBMED
ScienceOn
|
26 |
Van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B Jr, Wanders RJ, et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with 'Lorenzo's oil'. J Neurol Neurosurg Psychiat 1999;67: 290-9
DOI
|